What is retatrutide?
Retatrutide is an investigational injection that activates three hormone receptors: GIP, GLP-1 and glucagon. The interest comes from substantial weight loss in human trials, followed by improvements in blood sugar and other measured outcomes. Published phase 3 results are now available. It is still not an FDA-approved medicine.
Those two facts belong together. The evidence has moved beyond early testing, while approval, longer follow-up and some important outcome questions remain unresolved. The useful question is what each trial actually found, in which people, and at what cost in side effects.
What does the third hormone pathway add?
Semaglutide acts at GLP-1 receptors, while tirzepatide acts at GLP-1 and GIP receptors. Retatrutide also activates the glucagon receptor. Its development aims to combine effects on appetite and glucose regulation with effects on energy use and liver fat. Animal experiments support increased energy expenditure, but the human trials do not isolate how much each receptor contributes. Three targets alone do not establish that a medicine is better or safer. Liver study and mechanism discussion.
What did the obesity trials find?
The original 2023 phase 2 trial enrolled 338 adults. At 48 weeks, the highest studied dose averaged 24.2% weight loss, compared with 2.1% on placebo. Gastrointestinal effects were dose-related, and heart rate increased before declining later in the trial.
The larger TRIUMPH-1 phase 3 publication reported 2,339 randomized adults without diabetes. At 80 weeks, estimated weight reductions were 17.6%, 23.7% and 25.0% across the three retatrutide groups, compared with 3.9% on placebo. These were the paper's treatment-regimen estimates, which aim to account for treatment interruptions and discontinuation. They should not be mixed with higher estimates that assume continued treatment.
TRIUMPH-1 also found reduced knee pain in its osteoarthritis subgroup and fewer breathing interruptions in its obstructive sleep apnea subgroup. Those are meaningful findings beyond the scale. They do not demonstrate cartilage regrowth or make retatrutide an approved treatment for either condition. Gastrointestinal events were the most common adverse effects.
What changes when people have diabetes?
Results depend on the population. In TRIUMPH-2, 1,152 adults with overweight or obesity and type 2 diabetes were randomized. At 80 weeks, treatment-regimen estimates were 11.9%, 16.8% and 18.8% weight loss across the retatrutide groups, versus 5.1% with placebo. Blood-sugar control also improved.
The tradeoffs were clear. Diarrhea, nausea, low blood pressure and dysesthesia, meaning altered or unpleasant skin sensations, were more common with retatrutide. Permanent discontinuation because of adverse events or death occurred in about 12% and 8% of the two higher-dose groups, versus 5% with placebo. Investigators judged the deaths unrelated to the study treatment.
The separate TRANSCEND-T2D-1 trial randomized 537 people whose diabetes was inadequately controlled by diet and exercise alone. At 40 weeks, the highest-dose group had an average HbA1c reduction of 1.94 percentage points and weight reduction of 15.3%, versus 0.81 points and 2.6% with placebo. Adverse effects led to treatment discontinuation in 2% to 5% of retatrutide participants and none on placebo. These later studies build on the 2023 phase 2 diabetes trial; they do not make every dose or population equivalent.
Has it been compared directly with semaglutide?
Yes, but the newest result needs its source label. In an October 28, 2026 sponsor announcement, Lilly reported that the open-label TRANSCEND-T2D-2 trial compared retatrutide with injectable Ozempic 2 mg in 1,298 adults with type 2 diabetes. Its efficacy-estimand results showed weight loss of 19.5% and 20.9% with retatrutide versus 9.4% with Ozempic at 80 weeks. HbA1c fell by about 2.2 versus 1.8 percentage points.
Lilly reported adverse-event discontinuation rates of 4.8% and 7.9% with retatrutide versus 2.7% with Ozempic. Detailed peer-reviewed publication was still forthcoming in that announcement. This comparison does not establish superiority over Wegovy formulations or tirzepatide. The TRIUMPH-5 comparison with tirzepatide was active, not recruiting, with no posted results when checked.
What about liver fat and lean tissue?
A 98-person liver substudy of the phase 2 obesity trial used MRI in people with at least 10% liver fat. At 24 weeks, the highest-dose group had an 82.4% relative reduction in liver fat, versus a 0.3% increase with placebo. This was a relative change in fat content, not an 82-point fall or proof of reversing liver scarring. There were no liver biopsies, and more than half lacked a 48-week MRI, limiting the longer-term analysis.
A body-composition substudy in type 2 diabetes found greater fat loss at the higher doses, alongside lean-mass loss. The lowest dose did not significantly outperform placebo for fat loss. Although 189 people entered the substudy, only 103 completed treatment and both scans. The authors found a proportion of lean loss similar to other obesity treatments, but this does not establish preservation of muscle strength or function.
What remains unproven, and what is available?
Lower weight, blood sugar or liver fat does not by itself prove fewer heart attacks, kidney failures or deaths. TRIUMPH-Outcomes is examining cardiovascular and kidney events. Its current record lists an estimated 10,000 participants, no posted results and estimated completion in 2029. These are study plans, not findings.
In the United States, FDA states that retatrutide cannot be used in compounding under federal law and is not a component of an approved drug. A prescription or a seller's certificate does not turn an unapproved vial into the product tested in these trials. A useful clinical conversation can compare approved options and any legitimate trial opportunities without assuming future approval or a filing date is guaranteed.
Where the evidence stands
Published trials
Phase 2 and phase 3 trials show substantial weight and glucose effects in specific populations.
Other outcomes
Knee pain and sleep apnea improved in TRIUMPH-1 subgroups; liver findings remain based on imaging.
Still being tested
Cardiovascular and kidney event reduction and longer-term safety remain open questions.
Current access
Retatrutide remains investigational and is not FDA-approved. U.S. compounding is not permitted.
The TRIUMPH-1 registry has no posted results even though a peer-reviewed paper exists. Registry postings, journal publications and sponsor announcements are separate sources. Related records are searchable on our Science page.
Questions people ask
Is the 24% weight-loss result still relevant?
Yes. It was the highest-dose average in a 338-person phase 2 trial at 48 weeks. The later TRIUMPH-1 publication reported a 25.0% treatment-regimen estimate at the highest dose over 80 weeks, versus 3.9% with placebo. Different populations, durations and statistical approaches should not be treated as interchangeable.
Is retatrutide approved or available as a compounded medicine?
Retatrutide is not FDA-approved. FDA states that it cannot be used in compounding under U.S. federal law. Clinical-trial participation has separate eligibility and oversight; online availability does not establish approval or product quality.
Is it better than semaglutide or tirzepatide?
An October 2026 sponsor report found greater weight and HbA1c reductions than Ozempic 2 mg in adults with type 2 diabetes, with more adverse-event discontinuations. That is not a comparison with every semaglutide formulation. The direct tirzepatide trial had no posted results when checked, and cross-trial percentages cannot settle that comparison.
Do the liver results show that it reverses fibrosis?
No. The phase 2 liver substudy measured fat with MRI and did not include liver biopsies. It showed a substantial reduction in liver fat, but did not establish reversal of fibrosis or prevention of liver-related clinical events.
What to take away
- Retatrutide has published phase 3 evidence, including substantial average weight loss and improved glucose control.
- Population and analysis method change the numbers. Sponsor topline reports should remain labeled as such.
- Gastrointestinal effects, altered skin sensations, low blood pressure and treatment discontinuations matter alongside efficacy.
- Liver-fat reduction is not proof of fibrosis reversal, and cardiovascular and kidney event results are still pending.
- Retatrutide is not FDA-approved, and FDA does not permit its use in U.S. compounding.
The evidence
Selected original studies, trial records and regulatory sources checked November 9, 2026. Study doses describe the research and are not instructions for use.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Evidence and approvals apply to the products and populations described. Any treatment decision should be made with a qualified physician. Individual results vary.